Published in Transpl Int on November 12, 2007
Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. Transpl Int (2009) 0.75
Conversion to sirolimus of patients with chronic allograft nephropathy--a retrospective analysis of outcome and influencing factors. Langenbecks Arch Surg (2008) 0.75
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol (2013) 2.62
Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant (2004) 2.40
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation (2009) 2.28
In-vivo interaction of nitric oxide and endothelin. J Hypertens (2004) 2.20
A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med (2009) 2.20
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol (2013) 2.20
Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke. Stroke (2013) 2.07
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.93
New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nat Genet (2012) 1.90
A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. Nephrol Dial Transplant (2005) 1.87
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost (2013) 1.83
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis (2010) 1.83
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant (2004) 1.77
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation (2011) 1.66
Significant differentiation of focal breast lesions: calculation of strain ratio in breast sonoelastography. Acad Radiol (2010) 1.62
Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62
Low birth weight, a risk factor for cardiovascular diseases in later life, is already associated with elevated fetal glycosylated hemoglobin at birth. Circulation (2006) 1.61
Characterization of γδ T cell subsets in organ transplantation. Transpl Int (2010) 1.57
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens (2004) 1.51
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens (2002) 1.50
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant (2004) 1.50
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation (2015) 1.47
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract (2003) 1.46
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
Orthotopic kidney transplantation: an alternative surgical technique in selected patients. Eur Urol (2010) 1.45
No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant (2004) 1.43
The 'blood group O problem' in kidney transplantation--time to change? Nephrol Dial Transplant (2010) 1.42
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant (2004) 1.42
Integrating an evidence-based medicine rotation into an internal medicine residency program. Acad Med (2004) 1.41
FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. Transplantation (2004) 1.40
Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care (2005) 1.39
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
Influence of the ionic dialysance monitor on Kt measurement in hemodialysis. Am J Kidney Dis (2008) 1.39
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation (2008) 1.34
Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis (2004) 1.30
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Age and immune response in organ transplantation. Transplantation (2005) 1.23
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation (2010) 1.20
Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics (2009) 1.18
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol (2004) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant (2002) 1.11
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant (2005) 1.11
Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit (2009) 1.11
Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol (2007) 1.10
Long-term outcomes after acute kidney injury. Crit Care Med (2008) 1.09
Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev (Orlando) (2011) 1.09
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol (2003) 1.09
Old-for-old kidney allocation allows successful expansion of the donor and recipient pool. Am J Transplant (2003) 1.08
Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol (2010) 1.07
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics (2008) 1.07
Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol (2011) 1.05
Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J (2002) 1.05
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant (2004) 1.05
Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis (2004) 1.05
Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology (2002) 1.04
Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol (2007) 1.03
Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant (2003) 1.03
The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol (2003) 1.01
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics (2009) 1.00
The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Transplantation (2014) 0.99
Pregnancy on intensified hemodialysis: fetal surveillance and perinatal outcome. Fetal Diagn Ther (2007) 0.99
Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial (2012) 0.98
Determinants of knowledge gain in evidence-based medicine short courses: an international assessment. Open Med (2010) 0.98
Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant (2013) 0.97
Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet (2010) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int (2008) 0.97
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf (2014) 0.97
Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant (2005) 0.96
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther (2004) 0.96
Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med (2014) 0.95
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant (2011) 0.95